Voke® licence - variation granted by MHRA

News Release

23 February 2015

Voke® nicotine inhaler licence - variation granted by MHRA

Hemel Hempstead, UK, 23 February 2015 - Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading, global single source drug and delivery company, can confirm that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Kind Consumer the variation to the first Marketing Authorisation awarded to the Voke® nicotine inhaler, the subject of Bespak's development programme DEV200.

The first Marketing Authorisation for the Voke® nicotine inhaler was received in September 2014. Nicovations, a wholly owned subsidiary of British American Tobacco plc, is Consort's customer for this programme and will commercialise the product.

As previously announced, the production facilities which will house the Voke® production line, are in place at Bespak in King's Lynn. Consort continues to work closely with Nicovations to complete scale up for full commercialisation, details of which will be announced by Nicovations at the appropriate time.

Notes:

Voke® is an innovative nicotine inhalation device for smokers. Voke® involves no heat or combustion, and so produces no ash or smoke. It also requires no battery or other energy source, it is activated simply by the user inhaling.

Voke® was developed by Kind Consumer Limited.

Voke® will be commercialised by Nicovations, a wholly owned subsidiary of British American Tobacco plc.

-Ends-

Enquiries:

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.